Endogena Therapeutics, Inc.’s Post

During Dry Eye Awareness month, I am excited to spotlight Oculis’ pioneering efforts in advancing innovative solutions for Dry Eye patients worldwide. With an estimated 300 million individuals affected by DED, a staggering 87% of patients express dissatisfaction with current treatment options due to the disease's heterogeneity. Aligned with Oculis commitment to Rethinking Ophthalmology, we recently shared promising data from the RELIEF trial for signs of DED. This represents a significant stride towards potentially transforming DED treatment through #PrecisionMedicine with OCS-02 (licaminlimab), an innovative anti-TNF-α antibody eye drop tailored for topical administration. The trial showed efficacy across various DED signs, with a remarkable 5 times greater treatment effect in signs for patients with a specific TNFR1-related genotype, which was consistent with the 7 times greater effect in symptoms observed in a previous trial in the same genotype population underscoring the unprecedented benefits of a predictive and personalized medicine approach. As we tackle the substantial unmet needs in DED, recognizing the disease's complexity and the diverse patient population, our primary focus remains on advancing #innovation in precision medicine to step change outcomes for patients. #DryEyeAwareness #Biotech #ClinicalTrials #EyeHealth #EyeDisease

We are pleased to share a significant milestone in our journey at Cirrus Therapeutics, an ocular immunology-focused company my partner in crime Andrew Dick and I co-founded. Our recent research, published in #ScienceTranslationalMedicine, introduces a pioneering approach to treating age-related macular degeneration (#AMD). By enhancing IRAK-M protein levels in retinal cells, we have developed a promising new therapy for AMD, the leading cause of vision loss in older adults. This discovery, made in collaboration with esteemed researchers from the University of Bristol and the UCL Institute of Ophthalmology, including the super talented Jian Liu and Dave Copland, represents a pathway-agnostic solution offering comprehensive treatment options for dry AMD. This innovative approach aims to address the complex pathophysiology of AMD, providing hope to millions affected by this debilitating condition. We extend our gratitude to the Rosetrees Trust, Stoneygate Trust, Underwood Trust, Macular Society, Sight Research UK, NIHR Moorfields Biomedical Research Centre, UCL Institute of Ophthalmology, our other supporters who have made this research possible. Many thanks to our incredible advisors James Handa, Frank G. Holz, Brian Mansfield and Maritza McIntyre for their unwavering support and expert guidance. As we continue to advance our lead program and engage with investors, we remain committed to our mission of developing cutting-edge treatments for long-term eye diseases that can cause blindness. Read more about the publication here: https://lnkd.in/gFvJkdCE #Ophthalmology #VisionCare #ScientificResearch #CirrusTherapeutics #HealthcareInnovation

🎥 Take a look at this insightful interview with Dr. Michael Belin, Chief Medical Officer of Epion Therapeutics! At International Keratoconus Academy's Second Annual Keratoconus Symposium, Dr. Belin coached the audience in how to use the 𝗔𝗕𝗖𝗗 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀𝗶𝗼𝗻 𝗗𝗶𝘀𝗽𝗹𝗮𝘆 🔠, which he developed to classify disease severity and help diagnose keratoconus earlier. 𝗧𝗵𝗲 𝗕𝗲𝗹𝗶𝗻 𝗔𝗕𝗖𝗗 𝗰𝗹𝗮𝘀𝘀𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘂𝘀𝗲𝘀 𝗳𝗼𝘂𝗿 𝗸𝗲𝘆 𝗽𝗮𝗿𝗮𝗺𝗲𝘁𝗲𝗿𝘀 𝘁𝗼 𝗱𝗲𝘁𝗲𝗿𝗺𝗶𝗻𝗲 𝗸𝗲𝗿𝗮𝘁𝗼𝗰𝗼𝗻𝘂𝘀 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀𝗶𝗼𝗻: 🅰 = Anterior radius of curvature 🅱 = Back (posterior radius of curvature) 🅲 = minimal Corneal thickness 🅳 = Distance visual acuity The ABCD Progression Display – available on the OCULUS, Inc. #Pentacam – allows physicians to track the progression of ectatic disease for up to 8 exams. 🩺👁️ This breakthrough could mean earlier detection and treatment with cross-linking, preserving vision for countless patients. 🌟 #Ophthalmology #Innovation #Keratoconus #PatientCare #MedicalAdvances

Listen to learn about the ABCD Progression Display! #Early Detection#Epion#Epi-on#Keratoconus#Optometry#cross-linking

📮🥳Just received my April/May issue of Eye News in the post 🥳 The digital version is available here: https://lnkd.in/eM-sqts2 Advocates of the old-school can subscribe here for a print copy (free in the United Kingdom and Republic of Ireland): https://lnkd.in/eTWcnpwC Two features from me - one is a brief summary of our Medical Ophthalmology Society UK (MOSUK) 2024 meeting in the Newsround section, and the second is an early 2024 #Oculomics review, gently adducing the fascinating links between the eye and systemic disease: https://lnkd.in/eNKa5e28 Advancements in technology like imaging, AI, and #bigdata are enabling the detection of previously undiscovered connections and risk factors at earlier stages, and fascinating links are being unveiled. For example, associations between childhood lazy eye and increased risk of hypertension, obesity, and heart attacks in adulthood, as well as links between retinal thickness and gum disease, and the potential for screening rare conditions like #moyamoya disease through retinal imaging. This year, The Royal College of Ophthalmologists (RCOphth) annual congress is including a session on "Oculomics: re-linking the eye and the body" to explore this rapidly evolving field. As more biomarkers are discovered, there is a potential to revolutionize predictive, preventive, and #personalizedmedicine by enabling earlier intervention and tailored treatment strategies. Not only that, but we can develop low-cost screening methods to improve access to preventive care globally. Looking ahead to 2024 and beyond, the focus is on expanding #biomarkers beyond imaging modalities to include molecular and histologic characteristics, offering promise for early detection of diseases like Alzheimer's. The UK Biobank and other global biomedical databases are feeding this research and it is an exciting time. Watch this space. If you are an expert and want to contribute your insights, please feel free to connect (details at the bottom of this article: https://lnkd.in/eNKa5e28)

Hot off the HoloCare press: we’ve been awarded an €8.9 million Horizon Europe grant for HoloSurge, our new Europe-wide surgical hologram research collaboration! HoloSurge is a four-year project that unites 14 European leaders in technology and healthcare research. Together, we share a common goal: to reduce the risk of complications during planned surgery. The €8.9 million EU grant will fund the further development of organ hologram technology to power informed surgical decision-making. “Horizon Europe is not just about funding; it's about forging connections, driving innovation, and shaping the future of healthcare. The HoloSurge partnership stands as a testament to this. Through joint efforts we’re aiming to use our hologram technology to transform the surgical outcomes of individuals worldwide.” - Jahn Otto Andersen, Innovation Director at HoloCare Thank you to our partners, who we are set to embark on this collaborative journey with: SINTEF, Oslo University Hospital, The Netherlands Cancer Institute, University of Leeds and Leeds Teaching Hospitals NHS Trust, LMU Klinikum München, Maria Sklodowska-Curie National Research Institute of Oncology, Metropolia University of Applied Sciences, Orbit 21 Consulting Ltd, CYENS Centre of Excellence, Semmelweis University Center for Health Technology Assessment, UEG - United European Gastroenterology, Digestive Cancers Europe Read our full announcement ➡️ https://lnkd.in/eVT8pzjK #surgery #mixedreality #holocare #digitalhealth #healthtech

Join the All Star Panelists, Arshad M. Khanani; Firas M. Rahhal, MD; Ram Palanki; George Magrath; and Maryam Mokhtarzadeh, M.D. at the Association for Research in Vision and Ophthalmology (ARVO) Special Interest Group (SIG) discussion on "Oral Medications for Management of Retinal Diseases". The session is being moderated by Charles DeBoer and myself. With many attempts to address to treatment burden for both patients and clinicians, oral medications appear to have become a significant focus as a likely treatment option for retinal diseases. This SIG will discuss the various programs and the background information about what it takes to plan and implement an oral med clinical study, various endpoints, what the regulators are likely to look at for approval, and what will it take to commercialize and market these products if and when they get approved. We also encourage the audience to partake in the discussion - we welcome questions and will raise these questions in front of the panel during the SIG. Feel free to ask any questions you may have. Join us for this interesting conversation - the SIG is on July 11, 2024, 3-430pm PST. If you haven't registered, please do so quickly. The panel and the moderators are looking forward to this event!

👁 Unlock the potential of zebrafish models in advancing ophthalmology research! Explore their genetic parallels to humans and their role in behavioral visual assessments. 🐟 Dive into this insightful blog article to uncover how zebrafish are shaping the future of eye disease treatments. Don't miss out! 👉 https://bit.ly/3WnsrM8 #OphthalmologyResearch #Zebrafish #DrugDiscovery

Check out what beautiful precision imaging looks like with Akumin®

🌟 Exciting news for Ophthalmologists! We're thrilled to announce the upcoming launch of our Discovery platform and AI imaging analysis for Clinics! With Discovery, you’ll have access to AI-enhanced visualisations on OCT images, revealing up to 13 retinal features, including: ✅ 7 retinal layers (RNFL, GCL+IPL, INL+OPL, ONL+HFL, MZ, EZ+OPR+IZ, RPE) ✅ Choroid ✅ Subretinal Fluids ✅ Intra-retinal Fluids ✅ Pigment Epithelial Detachments / Drusen ✅ Hyper-Reflective Foci ✅ Amorphous Material This feature, designed for precise segmentation and quantification across 8 layers of the retina and choroid, with segmentation and volume quantification of IRF, SRF, PED, HRF and AM will enrich your disease understanding with important insights on biomarkers of disease progression. Prof. Marion Munk, M.D., Ph.D, a user of Discovery, shares her experience: “Explaining retinal conditions in terms of fluid volumes rather than pointing out lesions has significantly improved my patient interactions. It becomes a volume they can visualize. I remember a patient who missed seeing this on the platform and asked if we could revisit it on Discovery for a clearer understanding.” Get ready to transform your patient care with intuitive, precise, and quantifiable metrics. Join our waitlist for an early peek: https://lnkd.in/ebqf2Bef